CYTEK BIOSCIENCES, INC. Net Income (Loss) Available to Common Stockholders, Basic
CYTEK BIOSCIENCES, INC. (CTKB) reported Net Income (Loss) Available to Common Stockholders, Basic of -$12.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-05
- CYTEK BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$12.16M.
- CYTEK BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$18.87M.
- CYTEK BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$44.08M, a 557.08% decline year-over-year.
- CYTEK BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$5.48M, a 682.15% decline year-over-year.
- CYTEK BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$66.54M.
- CYTEK BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$6.02M.
- CYTEK BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$12.15M, a 571.58% decline from fiscal 2022.
- CYTEK BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was $2.58M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.16M 10-Q · filed 2026-08-05 | -$31.02M 10-Q · filed 2026-08-05 | -$75.10M derived: sum of 3 quarters · filed 2026-08-05 | -$80.58M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$18.87M 10-Q · filed 2026-05-07 | -$62.94M derived: sum of 2 quarters · filed 2026-05-07 | -$68.42M derived: sum of 3 quarters · filed 2026-05-07 | -$74.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$44.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$49.55M derived: sum of 2 quarters · filed 2026-02-26 | -$55.14M derived: sum of 3 quarters · filed 2026-08-05 | -$66.54M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$5.48M 10-Q · filed 2025-11-05 | -$11.06M derived: sum of 2 quarters · filed 2026-08-05 | -$22.46M 10-Q · filed 2025-11-05 | -$12.82M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$5.58M 10-Q · filed 2026-08-05 | -$16.98M 10-Q · filed 2026-08-05 | -$7.34M derived: sum of 3 quarters · filed 2026-08-05 | -$6.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$11.40M 10-Q · filed 2026-05-07 | -$1.76M derived: sum of 2 quarters · filed 2026-05-07 | -$818.00K derived: sum of 3 quarters · filed 2026-05-07 | -$11.25M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $9.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.58M derived: sum of 2 quarters · filed 2026-02-26 | $150.00K derived: sum of 3 quarters · filed 2026-02-26 | -$6.02M 10-K · filed 2026-02-26 |
| 2024-09-30 | $941.00K 10-Q · filed 2025-11-05 | -$9.49M derived: sum of 2 quarters · filed 2025-11-05 | -$15.66M 10-Q · filed 2025-11-05 | -$10.16M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$10.43M 10-Q · filed 2025-08-06 | -$16.60M 10-Q · filed 2025-08-06 | -$11.10M derived: sum of 3 quarters · filed 2026-02-26 | -$17.56M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$6.17M 10-Q · filed 2025-05-08 | -$666.00K derived: sum of 2 quarters · filed 2026-02-26 | -$7.12M derived: sum of 3 quarters · filed 2026-02-26 | -$11.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$953.00K derived: sum of 2 quarters · filed 2026-02-26 | -$5.34M derived: sum of 3 quarters · filed 2026-02-26 | -$12.15M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$6.46M 10-Q · filed 2024-11-07 | -$10.84M derived: sum of 2 quarters · filed 2024-11-07 | -$17.65M 10-Q · filed 2024-11-07 | -$14.12M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | -$4.39M 10-Q · filed 2024-11-07 | -$11.20M 10-Q · filed 2024-08-06 | -$7.67M derived: sum of 3 quarters · filed 2025-02-28 | -$6.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | -$6.81M 10-Q · filed 2024-11-07 | -$3.28M derived: sum of 2 quarters · filed 2025-02-28 | -$1.61M derived: sum of 3 quarters · filed 2025-02-28 | -$2.21M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $5.20M derived: sum of 2 quarters · filed 2025-02-28 | $4.60M derived: sum of 3 quarters · filed 2025-02-28 | $2.58M 10-K · filed 2025-02-28 |
| 2022-09-30 | $1.67M 10-Q · filed 2023-11-14 | $1.07M derived: sum of 2 quarters · filed 2023-11-14 | -$953.00K 10-Q · filed 2023-11-14 | -$953.00K derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | -$598.00K 10-Q · filed 2023-11-14 | -$2.62M 10-Q · filed 2023-08-08 | -$2.62M derived: sum of 3 quarters · filed 2024-03-13 | -$2.27M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | -$2.02M 10-Q · filed 2023-11-14 | -$2.02M derived: sum of 2 quarters · filed 2024-03-13 | -$1.68M derived: sum of 3 quarters · filed 2024-03-13 | -$1.68M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $346.00K derived: sum of 2 quarters · filed 2024-03-13 | $346.00K derived: sum of 3 quarters · filed 2024-03-13 | $0.00 10-K · filed 2024-03-13 |
| 2021-09-30 | $346.00K 10-Q · filed 2022-11-09 | $346.00K derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $921.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 | $575.00K derived: sum of 3 quarters · filed 2023-03-01 | $2.02M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 | $575.00K derived: sum of 2 quarters · filed 2023-03-01 | $2.02M derived: sum of 3 quarters · filed 2023-03-01 | $3.92M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $575.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $2.02M derived: sum of 2 quarters · filed 2023-03-01 | $3.92M derived: sum of 3 quarters · filed 2023-03-01 | $3.22M 10-K · filed 2023-03-01 |
| 2020-09-30 | $1.45M 10-Q · filed 2021-11-12 | $3.35M derived: sum of 2 quarters · filed 2021-11-12 | $2.64M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $1.90M 10-Q · filed 2021-09-03 | $1.20M 10-Q · filed 2021-09-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |